Delving into the Latest Updates on Amphetamine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+-)-alpha-Methylphenylethylamine, 1-phenyl-2-aminopropane, Adzenys XR-ODT

+ [14]

Target

TAAR1

Mechanism

TAAR1 agonists(Trace amine-associated receptor 1 agonists), Central nervous system stimulants

Therapeutic Areas

Other Diseases

Active Indication

Attention Deficit Disorder With HyperactivityPsychotic Disorders

Inactive Indication-

Originator Organization

Neos Therapeutics, Inc.

Active Organization

The Howard Hughes Medical Institute

Neos Therapeutics, Inc.

Inactive Organization

Tris Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

US (27 Jan 2016),

Attention Deficit Disorder With Hyperactivity

Regulation-

Login to view timeline

Structure

Molecular FormulaC9H13N

InChIKeyKWTSXDURSIMDCE-UHFFFAOYSA-N

CAS Registry300-62-9

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.

Start Date01 Oct 2023

Sponsor / Collaborator

Nationwide Children's Hospital

[+13]

IRCT20210525051403N1 / RecruitingPhase 2/3IIT

Mindfulness Based Relapse Prevention Therapy in Individuals with Amphetamine Use Disorder

Start Date10 Jun 2021

Sponsor / Collaborator-

100 Clinical Results associated with Amphetamine

Login to view more data

100 Translational Medicine associated with Amphetamine

Login to view more data

100 Patents (Medical) associated with Amphetamine

Login to view more data

18,309

Literatures (Medical) associated with Amphetamine

01 Jan 2025·Behavioural Brain Research

Environmental enrichment and sex, but not n-acetylcysteine, alter extended-access amphetamine self-administration and cue-seeking

Article

Author: Cain, Mary E ; Azuma, Miki C ; Fort, Troy D ; Laux, Dylan A

There are no approved therapeutics for psychostimulant use and recurrence of psychostimulant use. However, in preclinical rodent models environmental enrichment can decrease psychostimulant self-administration of low unit doses and cue-induced amphetamine seeking. We have previously demonstrated that glutamate-dependent therapeutics are able to alter amphetamine seeking to amphetamine-associated cues only in enriched rats. In the current experiment, we will determine if enrichment can attenuate responding and cue-induced amphetamine seeking during extended access to a high dose of intravenous amphetamine. We will also determine if N-acetylcysteine (NAC), a glutamate dependent therapeutic, can attenuate amphetamine seeking in differentially reared rats. Female and male Sprague-Dawley rats were reared in enriched, isolated, or standard conditions from postnatal day 21-51. Rats were trained to self-administer intravenous amphetamine (0.1 mg/kg/infusion) during twelve 6-hour sessions. During the abstinence period, NAC (100 mg/kg) or saline was administered daily. Following a cue-induced amphetamine-seeking test, astrocyte densities within regions of the medial prefrontal cortex (mPFC) and nucleus accumbens (ACb) were quantified using immunohistochemistry. Environmental enrichment decreased responding for amphetamine and during the cue-induced amphetamine-seeking test. NAC did not attenuate cue-induced amphetamine seeking or alter astrocyte density. Across all groups, female rats self-administered less amphetamine but responded more during cue-induced amphetamine seeking than male rats. While amphetamine increased astrocyte densities within the ACb and mPFC, it did not alter mPFC astrocyte densities in female rats. The results suggest that enrichment can attenuate responding during extended access to a high dose of amphetamine and the associated cues. Sex alters amphetamine-induced changes to astrocyte densities in a regionally specific matter.

01 Dec 2024·Journal of Substance Use and Addiction Treatment

California's Recovery Incentives Program: Implementation strategies

Article

Author: Trupiano, Dominic ; Peck, James A ; Thompson, Caitlin ; Loya, Carissa ; Freese, Thomas E ; Rawson, Richard ; Cooper, Madelyn ; Rawson, Richard A ; Rutkowski, Beth A. ; Datrice, Adrienne ; Padwa, Howard ; Peck, James A. ; Rutkowski, Beth A ; Freese, Thomas E. ; Simmons, Julian

INTRODUCTIONDue to the increasing role of psychostimulants in the US drug poisoning crisis, there is an increasing need to effectively implement evidence-based treatment for individuals with stimulant use disorder (StimUD). Contingency management is a behavioral strategy with robust evidence of support for the treatment of StimUD. In 2023, California initiated a large-scale effort to implement CM as a treatment for individuals with a stimulant use disorder (cocaine, methamphetamine, amphetamine) called the Recovery Incentives Program: California's Contingency Management Benefit.METHODSThe Recovery Incentives Program is being systematically implemented using the Becker et al. Science to Service Lab (SSL) implementation approach with several augmentations for this project. The SSL features three core components: didactic training, performance feedback, and external facilitation. We have augmented this approach with a readiness assessment process for sites prior to CM service launch, and an ongoing fidelity monitoring and feedback component post-launch.RESULTSThe present paper is a preliminary report describing the use of this augmented SSL strategy for CM implementation in a large-scale implementation effort. Data are presented to describe the implementation activities during the first ten months of the Recovery Incentives Program.CONCLUSIONThe California Recovery Incentives Program has been systematically implemented and appears to be receiving a positive response from treatment program staff and enrolled members. Future papers and evaluation reports will continue to document member response to the Program and report on the ongoing training and implementation process.

01 Nov 2024·Bioorganic & Medicinal Chemistry Letters

Design, synthesis, and activity evaluation of water-soluble propofol derivatives as anesthetic drugs

Article

Author: Zhu, Linyuan ; Li, Hongji ; Li, Wen ; Huang, Yanxin ; Zeeshan, Muhammad ; Jing, Chenyang

In this work, two series of water-soluble derivatives were designed and synthesized based on the structure of propofol as the lead compound. Furthermore, the anesthetic activities of the synthesized compounds were evaluated in vivo against mice, and the in vitro propofol release rate from five target compounds was determined. The findings of this study have shown that series II compounds which possess the structure feature of propofol + γ-hydroxybutyric acid + α-aminoacetate or γ-aminobutyrate have higher therapeutic index than that of series I compounds which possess the structure feature of propofol + α-aminoacetate or β-aminopropionate. In addition, the rate of propofol released from series II compounds was significantly better than that of series I compounds. Among series II compounds, compound II-20 had a therapeutic index of 5.6 (propofol = 2.7), a duration time of 571 s (propofol = 57 s), and no significant toxicity was observed in vivo, which made it valuable for further development.

119

News (Medical) associated with Amphetamine

24 Oct 2024

·www.prnewswire.com

Montana: A Trailblazer in Eliminating Regulatory Barriers for Opioid Use Disorder Treatment, According to Community Medical Services

HELENA, Mont., Oct. 24, 2024 /PRNewswire/ -- When the Substance Abuse and Mental Health Services Administration (SAMHSA) updated their recommendations governing Opioid Treatment Programs (OTPs) in April 2024, Montana was among the first to implement significant changes for OTPs in the state. Community Medical Services (CMS) currently provides care to Montana residents at 4 clinics, (Billings, Bozeman, Kalispell and Missoula), and has been working to adjust their clinical guidance to institute these changes aimed at improving patient safety and retention in treatment programs. This is a crucial step forward in addressing the opioid epidemic, providing more effective care for individuals struggling with opioid use disorder. Extended Take-Home Doses Under the new rules, patients are no longer required to come to a clinic at the same frequency as they have historically needed to. Medical providers can determine the appropriate number of take-home doses based on individual patient needs and criteria, including: Absence of active substance use disorders or other health conditions that increase the risk of patient harm Regular attendance for supervised medication administration Absence of serious behavioral problems Absence of known recent diversion activity Safe transportation and storage of take-home medication Higher Initial Dosing The initial dose of methadone, which was historically capped on the first day, can now be titrated more quickly at the medical provider's discretion, allowing patients with higher opioid tolerance to get to a therapeutic dose more quickly. This change acknowledges the varying levels of opioid tolerance among patients, exacerbated by the increased presence of fentanyl in the illicit drug supply, and enables medical providers to tailor treatment to individual needs. Drug Screens The presence of unprescribed amphetamine or cocaine on drug screen results will no longer be the sole limiting factor to requiring patients to not have to come into clinics daily, unless it increases the risk of overdose. This change recognizes that patients with opioid use disorder may also struggle with other substance use disorders and requires medical providers to assess each patient's unique situation. Conclusion The SAMHSA Final Rule changes mark a crucial step forward in enhancing Opioid Treatment Programs in Montana. By providing more flexible and individualized treatment options, these changes aim to improve patient safety and retention, decrease daily patient volumes at clinics, and ultimately support individuals in their journey towards recovery. How CMS is Implementing SAMHSA's Changes At its 4 clinics in Montana, CMS has proactively implemented the SAMHSA Final Rule changes. Our approach focuses on balancing patient safety with reducing barriers to treatment, ensuring that any changes benefit our patients and their recovery outcomes. Triweekly dosing—allowing patients to come to the clinic only three times per week—has become the new standard. This means that most patients, even those who might test positive for stimulants or miss some clinic days, are not required to visit the clinic more than three times a week. For patients who meet certain stability criteria, the option to advance to weekly clinic visits is available after just two weeks of triweekly dosing. This provides immense relief to patients who previously struggled to balance daily trips to the clinic with their other responsibilities, such as work or family. Visit the CMS blog on our website for a complete review by our Chief Science Officer, Dr. Robert Sherrick, of how we are taking an active step toward implementing these changes and seeing early positive results Media Contact: John Koch- Director Public Relations [email protected] 2827 Fort Missoula Rd, Missoula, MT 59804 8707 Jackrabbit Ln Suite D, Belgrade, MT 59714 2415 S Catlin St, Missoula, MT 59801 795 Sunset Blvd F, Kalispell, MT 59901 2040 Rosebud Dr, Billings, MT 59102 2827 Fort Missoula Rd, Missoula, MT 59804 SOURCE Community Medical Services WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

19 Sep 2024

·www.biospace.com

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Thursday, September 26, 2024. The Company has scheduled a conference call and webcast that same day, Thursday, September 26, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session. Conference Call Details Date and Time: Thursday, September 26, 2024, at 4:30 p.m. Eastern time. Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 216512. Webcast Information: The webcast will be accessible live and archived at , and accessible on the Investors section of the Company’s website at under Events & Presentations. Replay: A teleconference replay of the call will be available until October 10, 2024, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 51231. About Aytu BioPharma, Inc. Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com. Contacts for Investors Mark Oki, Chief Financial Officer Aytu BioPharma, Inc. moki@aytubio.com Robert Blum or Roger Weiss Lytham Partners aytu@lythampartners.com SOURCE: Aytu BioPharma, Inc. View the original press release on accesswire.com

Financial Statement

12 Sep 2024

·www.drugs.com

High Doses of ADHD Meds Could Trigger Psychosis

THURSDAY, Sept. 12, 2024 -- Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately, high doses of stimulants like Adderall can increase the risk of psychosis or mania by more than fivefold, a new study finds. Patients had a nearly 63% increased risk of psychosis or mania if they took any prescription amphetamine within the past month, researchers reported Sept. 12 in the American Journal of Psychiatry . Those on heavy doses of amphetamines were at even greater peril of a psychotic episode, with an 81% increased risk, results show. The highest risk occurred in patients taking 30 milligrams or more of dextroamphetamine, which corresponds to 40 milligrams of Adderall, the study says. “Stimulant medications don’t have an upper dose limit on their labels, and our results show that it is clear that dose is a factor in psychosis risk and should be a chief consideration when prescribing stimulants,” said lead investigator Dr. Lauren Moran , a pharmacoepidemiology researcher at McLean Hospital in Belmont, Mass. “This is a rare but serious side effect that should be monitored by both patients and their doctors whenever these medications are prescribed,” Moran added. Moran said she pursued this study based on her experiences as an inpatient psychiatrist. She and her Mclean colleagues would regularly see patients experiencing their first episode of psychosis. Medical records would reveal the patients had been prescribed high doses of stimulants by their doctors. For the study, researchers analyzed data on nearly 1,400 patients admitted to Mass General Brigham Hospital between 2005 and 2019 who were in the throes of their first episode of psychosis or mania. They compared those patients against more than 2,700 people hospitalized for other psychiatric conditions like depression or anxiety. They found that people taking amphetamines had a higher risk of psychosis and mania, and that the risk was greatest with heavy doses. This link could be explained by the fact that amphetamines prompt the release of dopamine, a brain hormone also implicated in psychosis, researchers said. People taking amphetamines for ADHD shouldn’t be alarmed, Moran said, but they might want to talk with their doctor about the dosage they’ve been prescribed. There also are alternative drugs to treat ADHD that don’t increase mental health risk. For example, this study found no increased risk of psychosis or mania in prescriptions for methylphenidate (Ritalin), Moran noted. “There’s limited evidence that prescription amphetamines are more effective in high doses,” Moran said in a Mass General Brigham news release. “Physicians should consider other medications our study found to be less risky, especially if a patient is at high risk for psychosis or mania.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Amphetamine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Amphetamine	N06BA01	DB00182

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	US	Neos Therapeutics, Inc.	27 Jan 2016

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	Phase 1	US	Tris Pharma, Inc.	06 Feb 2019
Psychotic Disorders	Discovery	US	The Howard Hughes Medical Institute	18 Dec 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03772314 (CTgov)	Phase 2	Narcolepsy \| Idiopathic Hypersomnia	44	Modafinil (Modafinil)	cbfnmkurvi(gpsjxqemqt) = xrfbkpuhgq agqxzvwkae (fzprdqhkmo, zillsvhxrf - lyllkkaerb) View more	-	23 May 2024
				dextroamphetamine (Amphetamine-dextroamphetamine)	cbfnmkurvi(gpsjxqemqt) = lzonefeefa agqxzvwkae (fzprdqhkmo, sgwkqlskzd - mfmcztgqdr) View more
NCT03834766 (CTgov)	Phase 3	Attention Deficit Disorder With Hyperactivity	130	20 mg (AMPH ER Tab)	uzijneatyy(olfpfbtkxi) = bvilvejplz maypykbmtf (juuqxkmwva, pzqqmdhirl - qvyhwzbtxt) View more	-	02 Nov 2023
				AMPH ER Tab Matching Placebo 5, 10, 15 (Matching Placebo)	uzijneatyy(olfpfbtkxi) = imevpjlfmp maypykbmtf (juuqxkmwva, nhvxmwzloz - uwwiyrqvdq) View more
NCT02058693 (CTgov)	Phase 4	Major depressive disorder, moderate (MDD) \| Depressive Disorder, Major	41	mixed salts amphetamine (Group 1(A): Placebo/MSA)	raqdwtvxkz(psanmkidvj) = glgbrhrmrf eilaaxesnr (onzuexfqkx, nttftnvzmm - tqjnhldpei) View more	-	15 Jun 2023
				mixed salts amphetamine (Group 2(B): MSA/MSA)	raqdwtvxkz(psanmkidvj) = sxsgvejnws eilaaxesnr (onzuexfqkx, ykihznwcwl - hcpgfdrjzu) View more
NCT03242772 (CTgov)	Phase 2	Autism Spectrum Disorder \| Heart Septal Defects, Atrial \| Attention Deficit Disorder With Hyperactivity	18	ESDM informed parent coaching+Amphetamine (ESDM Informed Parent Coaching + Amphetamine)	lfkjdlcxgz(gwtdykgnpf) = wpgohwvqod jkalwytguw (cajcbdpwgm, bmrquhwbuk - kpjeskylcy) View more	-	09 Mar 2022
				ESDM informed parent coaching (ESDM Informed Parent Coaching + Placebo Oral Tablet)	lfkjdlcxgz(gwtdykgnpf) = scpqcdvunv jkalwytguw (cajcbdpwgm, goffafznzn - corwggjghv) View more
NCT02634684 (CTgov)	Phase 2	Schizophrenia \| Psychotic Disorders	82	Placebo+Amphetamine (Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine)	oxkcykgfen(stwwkxrtyp) = pudvzrtndo csxwodhukn (rjztxclyfl, ycmmvgicnr - gmabdbpfgp) View more	-	16 Aug 2021
				Placebo+Amphetamine (Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo)	oxkcykgfen(stwwkxrtyp) = ddtgtjrpgj csxwodhukn (rjztxclyfl, iylkhxkxjj - zwlxbcspyq) View more
NCT02083783 (CTgov)	Phase 3	Attention Deficit Disorder With Hyperactivity	108	TRI102 (TRI102)	vzubxoelvl(mmnfajlhng) = uktgnyqgam jjitqffuos (aplunfmrzw, qgcwxbkklb - tecxdlqzxk) View more	-	26 Aug 2020
				Placebo (Placebo)	vzubxoelvl(mmnfajlhng) = pblgtuzgbv jjitqffuos (aplunfmrzw, dtddpfbrqq - cxoigpjpya) View more
NCT02020408 (CTgov)	Phase 4	Binge-Eating Disorder	88	[11C]DASB+[11C]raclopride+amphetamine	tppdzbfjpl(pgfdvskrgg) = uwllhlmvkp gorhhplybc (nufwgluygd, leldxocfku - ttrnipadyb) View more	-	27 Apr 2020
NCT02959892 (CTgov)	Phase 1	-	12	[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)+Amphetamine+TAK -041 (TAK-041 20 mg)	fbhueqpybu(mvxiwlrxxq) = rybsskaagk kvetaynewo (uvdpdvaexj, ouymvoaxwl - fzxjuqfioi) View more	-	23 Dec 2019
				[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)+Amphetamine+TAK -041 (TAK-041 40 mg)	fbhueqpybu(mvxiwlrxxq) = ngwcvvmfwh kvetaynewo (uvdpdvaexj, hwvrsgdetv - yyaegcejzy) View more
NCT01847027 (CTgov)	Phase 2	-	23	NutraStem (Active Supplement)	jmgajiqdzv(yfahjrgatx) = pvkmnvsfis sieazizznu (hxobkjqvdt, vdxfleqxyh - qdryegeits) View more	-	29 May 2019
				Placebo (Sugar Pill)	jmgajiqdzv(yfahjrgatx) = cfimpalbdf sieazizznu (hxobkjqvdt, hlzyfhrdos - aaaattoovr) View more
NCT00218062 (CTgov)	Phase 2	Cocaine-Related Disorders	73	Therapy+D-Amphetamine 60mg (D-Amphetamine 60mg + Therapy)	ynxkqbjfdn(ynkyjipyhw) = zwtttjprwt bwqidqnlus (mpoczpeuiu, qzkflnopxl - stcqvdsxkw) View more	-	21 Jun 2017
				Therapy+Modafinil 400mg (Modafinil 400mg + Therapy)	ynxkqbjfdn(ynkyjipyhw) = bwnzkwutpu bwqidqnlus (mpoczpeuiu, iljckghwgk - hmhpvgpfet) View more